BRIEF published on 10/14/2024 at 17:26, 1 year 8 months ago Dalata Hotel Group PLC Announces Share Buyback Voting Rights Ordinary Shares Share Buyback Market Abuse Regulations Dalata Hotel Group
BRIEF published on 10/14/2024 at 17:26, 1 year 8 months ago Dalata Hotel Group PLC annonce un rachat d'actions Rachat D'actions Droit De Vote Actions Ordinaires Règlement Sur Les Abus De Marché Groupe Hôtelier Dalata
BRIEF published on 10/14/2024 at 17:20, 1 year 8 months ago Dalata Hotel Group PLC Concludes €30 Million Share Buy-back Programme Share Buy-back Shareholders Voting Rights Financial Strategy Dalata Hotel Group
BRIEF published on 10/14/2024 at 17:20, 1 year 8 months ago Dalata Hotel Group PLC conclut un programme de rachat d'actions de 30 millions d'euros Rachat D'actions Actionnaires Stratégie Financière Droit De Vote Groupe Hôtelier Dalata
BRIEF published on 10/14/2024 at 16:20, 1 year 8 months ago Icovy Marketing and Chamfr Unite to Support Medtech Suppliers Digital Marketing Innovation Acceleration Global Visibility Medtech Partnership Supplier Growth
BRIEF published on 10/14/2024 at 16:20, 1 year 8 months ago Icovy Marketing et Chamfr s'unissent pour soutenir les fournisseurs de technologies médicales Accélération De L'innovation Marketing Numérique Visibilité Mondiale Partenariat Medtech Croissance Des Fournisseurs
BRIEF published on 10/14/2024 at 16:13, 1 year 8 months ago Ad pepper media International N.V. Reports Q3 2024 EBITDA Growth Cost Optimization Revenue Decline EBITDA Growth Performance Marketing Q3 2024 Results
BRIEF published on 10/14/2024 at 16:13, 1 year 8 months ago Ad Pepper Media International NV annonce une croissance de l'EBITDA au troisième trimestre 2024 Baisse Des Revenus Optimisation Des Coûts Croissance De L'EBITDA Marketing De Performance Résultats Du 3e Trimestre 2024
BRIEF published on 10/14/2024 at 16:05, 1 year 8 months ago Laxxon Medical Unveils Oral GLP-1 Agonist at BIO Europe 2024 3D Printing Technology Pharmaceutical Innovation Oral GLP-1 Agonist Patient Compliance Weight Loss Treatment
BRIEF published on 10/14/2024 at 16:05, 1 year 8 months ago Laxxon Medical dévoile un agoniste oral du GLP-1 au salon BIO Europe 2024 Technologie D'impression 3D Innovation Pharmaceutique Agoniste Oral Du GLP-1 Conformité Des Patients Traitement De Perte De Poids
Published on 06/26/2026 at 14:05, 1 hour 3 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 1 hour 8 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 2 hours 8 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 2 hours 23 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 01:40, 13 hours 28 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/26/2026 at 14:00, 1 hour 7 minutes ago Hong Kong celebrates surge of global enterprises driving investment and opportunities
Published on 06/26/2026 at 14:00, 1 hour 8 minutes ago Bitcoin Group SE publishes 2025 Annual Report: Strategic realignment ensures future viability in the dynamic crypto market
Published on 06/26/2026 at 13:32, 1 hour 35 minutes ago Porsche ranks number one in J.D. Power 2026 U.S. Initial Quality Study
Published on 06/26/2026 at 13:30, 1 hour 37 minutes ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share
Published on 06/26/2026 at 13:30, 1 hour 37 minutes ago AlphaESS Unveils Expanded Energy Storage Ecosystem for Europe at Intersolar 2026
Published on 06/26/2026 at 07:00, 8 hours 8 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 8 hours 8 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
